A phase-specific benefit-toxicity framework for perioperative trials in muscle-invasive bladder cancer: A focused review andtrial-level mapping analysis.
The perioperative treatment landscape for muscle-invasive bladder cancer is changing rapidly with the emergence of immune checkpoint inhibitor- and antibody-drug conjugate-based strategies. Trials such as NIAGARA, EV-304/KEYNOTE-B15, and EV-303/KEYNOTE-905 have shown substantial improvements in event-free survival, ove...